I certainly don't know of any generic drug companies sub $250M enterprise value that have better prospects.
That’s not what I asked—I asked if there was any biotech company of any kind with a $250M enterprise value and better prospects than MNTA. If there is, I’d like to know about it!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”